So I was doing some thinking and I just dont believe that IPIX would release this interim data if it shouldbe construed as negative, the way that it is apparently being construed by people that may have something to gain from a drop in share price. IPIX are not obligated to release interim data. They are doing it because they know that it is positive data. Maybe SLCimmuno summarized it well by calling it a metaphorical "double" rather than a homerun, but that is only taking into account the interim results of reduction in incidence, not improvement to the healing time of once OM occurred in patients. As has been discussed, that is the SECONDARY endpoint which is the typical PRIMARY endpoint of all the rest of the competitors. I think once we see the secondary end points we realize that we have an "in the park homerun".

So I again ponder and ask: if IPIX was not confident in these results, then why would they have set themselves up for failure by releasing the data prior to top line analysis? It is because they are very good results, that is why!!
A partnership is coming.